Q-omics provides the consensus-scored PRAMEF19 profile across patient tissues and cancer cell-line models. PRAMEF19 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PRAMEF19 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, PRAMEF19 RNA expression shows 7,613 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, LUSC, and THYM as cancer lineages where PRAMEF19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRAMEF19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRAMEF19 survival associations across molecular data types. PRAMEF19 RNA expression shows survival associations in the most cancer types (10), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRAMEF19 RNA expression–survival associations across cancer types. High PRAMEF19 expression shows unfavorable associations in MESO, ACC, THCA, LIHC, THYM and CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PRAMEF19 RNA expression.
This table summarizes PRAMEF19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for PRAMEF19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRAMEF19 shows lower tumor expression in LUSC, KIRP and LUAD. The LUSC box plot shows higher PRAMEF19 RNA expression in normal versus tumor tissue (log2 FC = −0.025, t-test p = .008).
This table shows molecular features associated with PRAMEF19 in patient tissues and cancer cell lines. In patient samples, PRAMEF19 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRAMEF19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_NSCLC_LUAD.
